Skip to main content

Biogen Inc (BIIB-Q) Quote - Press Releases

Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (ACAD , BIIB , FLXN , DVAX , GBT )
- Comtex SmarTrend(R) - Fri Dec 6, 2:27AM CST
Comtex SmarTrend(R) - CMTX
Fri Dec 6, 2:27AM CST
Here are the top 5 stocks in the Biotechnology industry ranked by performance. We compiled the trading activity from yesterday and then analyzed the industry looking for stocks that were outperforming. This is what we found:
Biogen Announces Positive Phase 2 Study Results for Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus Erythematosus (SLE)
- Globe Newswire - Tue Dec 3, 6:30AM CST
Globe Newswire - CMTX
Tue Dec 3, 6:30AM CST
- The Phase 2 LILAC study met its primary endpoints, demonstrating statistically significant reduction of disease activity in patients with CLE and SLE who received BIIB059 compared to placebo
Watch for Biogen Inc to Potentially Rebound After Falling 1.28% Yesterday
- Comtex SmarTrend(R) - Mon Dec 2, 11:03AM CST
Comtex SmarTrend(R) - CMTX
Mon Dec 2, 11:03AM CST
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $290.16 to a high of $296.57. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $298.68 on volume of 281,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Presents Data Demonstrating Improved Gastrointestinal Tolerability With VUMERITY(TM) (diroximel fumarate) Compared to TECFIDERA(R) (dimethyl fumarate)
- GlobeNewswire - Fri Nov 22, 6:30AM CST
GlobeNewswire - CMTX
Fri Nov 22, 6:30AM CST
Biogen Inc. (Nasdaq: BIIB) today announced detailed results from the Phase 3 EVOLVE-MS-2 study demonstrating the improved patient-assessed gastrointestinal (GI) tolerability of VUMERITY(TM) (diroximel fumarate), a new FDA-approved treatment for relapsing forms of multiple sclerosis (MS), compared to TECFIDERA(dimethyl fumarate). These EVOLVE-MS-2 results are being presented at the 27 Annual Meeting of the European Charcot Foundation in Italy (Nov. 21-23).
Biogen Announces Enrollment Completion of Global Phase 3 Gene Therapy Study for an Inherited Retinal Disorder
- Globe Newswire - Thu Nov 21, 6:30AM CST
Globe Newswire - CMTX
Thu Nov 21, 6:30AM CST
Timrepigene emparvovec is a potential first-in-class AAV2 gene therapy for the treatment of choroideremia, a rare, degenerative, X-linked retinal disorder that leads to blindness
Cognition Therapeutics to Give Webcast Presentation at Annual Piper Jaffray Healthcare Conference on December 3, 2019
- GlobeNewswire - Wed Nov 20, 7:03AM CST
GlobeNewswire - CMTX
Wed Nov 20, 7:03AM CST
Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer's disease and other neurodegenerative disorders, today announced that President & CEO Kenneth I. Moch will present an update on the Company's lead Alzheimer's candidate, Elayta(TM), at the 31st Annual Piper Jaffray Healthcare Conference at 3:10 pm ET on December 3, 2019. Mr. Moch's presentation will be webcast live and archived on the Cognition website.
SmarTrend Watching for Potential Pullback in Shares of Biogen Inc After 1.44% Gain
- Comtex SmarTrend(R) - Tue Nov 19, 11:13AM CST
Comtex SmarTrend(R) - CMTX
Tue Nov 19, 11:13AM CST
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $280.51 to a high of $286.68. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $283.95 on volume of 89,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Inc Rises 28.48% on Heavy Volume: Watch For Potential Pullback
- Comtex SmarTrend(R) - Tue Nov 12, 10:50AM CST
Comtex SmarTrend(R) - CMTX
Tue Nov 12, 10:50AM CST
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $289.12 to a high of $296.25. Yesterday, the shares gained 28.5%, which took the trading range above the 3-day high of $294.92 on volume of 627,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Watch for Biogen Inc to Potentially Pullback After Gaining 28.48% Yesterday
- Comtex SmarTrend(R) - Tue Nov 12, 10:50AM CST
Comtex SmarTrend(R) - CMTX
Tue Nov 12, 10:50AM CST
Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $289.12 to a high of $296.25. Yesterday, the shares gained 28.5%, which took the trading range above the 3-day high of $294.92 on volume of 627,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY(TM)
- PR Newswire - Tue Nov 12, 6:00AM CST
PR Newswire - CMTX
Tue Nov 12, 6:00AM CST
Alkermes plc (Nasdaq: ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration (FDA) approval of VUMERITY(TM) (diroximel fumarate), a novel oral fumarate with a distinct chemical structure, for the treatment of relapsing forms of multiple sclerosis, and Alkermes' transfer to Biogen Inc. (Nasdaq: BIIB) of the New Drug Application and other regulatory documentation related to VUMERITY.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies